Literature DB >> 25110411

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.

Alfonso De Stefano1, Chiara Carlomagno1.   

Abstract

Systematic analysis of the epidermal growth factor receptor (EGFR) pathway revealed that biomarkers could be used to predict the response to and outcome of anti-EGFR therapies in patients affected by metastatic colorectal cancer. We have conducted a review on the most recent findings and advances on this topic. To this aim, we searched the PubMed database for articles devoted to predictive and prognostic biomarkers for patients administered cetuximab- and panitumumab-based therapies. Here we review the state of the art and the controversies about the molecular factors known to be predictors of the efficacy of anti-EGFR therapy, namely, KRAS, BRAF, NRAS, PI3KCA and PTEN, and we discuss their prognostic value in colorectal cancer patients.

Entities:  

Keywords:  Anti-epidermal growth factor receptor; Biomarkers; KRAS; Metastatic colorectal cancer

Mesh：

Substances：

Year:  2014        PMID： 25110411      PMCID： PMC4123362          DOI： 10.3748/wjg.v20.i29.9732

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  82 in total

1.  Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.

Authors:  Wendy De Roock; Derek J Jonker; Federica Di Nicolantonio; Andrea Sartore-Bianchi; Dongsheng Tu; Salvatore Siena; Simona Lamba; Sabrina Arena; Milo Frattini; Hubert Piessevaux; Eric Van Cutsem; Chris J O'Callaghan; Shirin Khambata-Ford; John R Zalcberg; John Simes; Christos S Karapetis; Alberto Bardelli; Sabine Tejpar
Journal:  JAMA       Date:  2010-10-27       Impact factor: 56.272

2.  Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.

Authors:  Chun-Nin Lee; Hsiang-Yin Chen; H Eugene Liu
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

3.  Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Authors:  Carsten Bokemeyer; Eric Van Cutsem; Philippe Rougier; Fortunato Ciardiello; Steffen Heeger; Michael Schlichting; Ilhan Celik; Claus-Henning Köhne
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

4.  Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Authors:  Nicolas Moosmann; Ludwig Fischer von Weikersthal; Ursula Vehling-Kaiser; Martina Stauch; Holger G Hass; Herrmann Dietzfelbinger; Daniel Oruzio; Stefan Klein; Klaus Zellmann; Thomas Decker; Mathias Schulze; Wolfgang Abenhardt; Gerhard Puchtler; Herbert Kappauf; Johann Mittermüller; Christopher Haberl; Andreas Schalhorn; Andreas Jung; Sebastian Stintzing; Volker Heinemann
Journal:  J Clin Oncol       Date:  2011-02-07       Impact factor: 44.544

5.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

Review 6.  Metastatic colorectal cancer-past, progress and future.

Authors:  Kathryn Field; Lara Lipton
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

Review 7.  Colon cancer overview.

Authors:  P Greenwald
Journal:  Cancer       Date:  1992-09-01       Impact factor: 6.860

8.  PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.

Authors:  Hans Prenen; Jef De Schutter; Bart Jacobs; Wendy De Roock; Bart Biesmans; Bart Claes; Diether Lambrechts; Eric Van Cutsem; Sabine Tejpar
Journal:  Clin Cancer Res       Date:  2009-04-14       Impact factor: 12.531

Review 9.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Authors:  Alberto Bardelli; Salvatore Siena
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

10.  KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

Authors:  F Loupakis; A Ruzzo; C Cremolini; B Vincenzi; L Salvatore; D Santini; G Masi; I Stasi; E Canestrari; E Rulli; I Floriani; K Bencardino; N Galluccio; V Catalano; G Tonini; M Magnani; G Fontanini; F Basolo; A Falcone; F Graziano
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640
View more
  17 in total

Review 1.  [Molecular pathology of colorectal cancer].

Authors:  J H L Neumann; A Jung; T Kirchner
Journal:  Pathologe       Date:  2015-03       Impact factor: 1.011

Review 2.  Pharmacologic resistance in colorectal cancer: a review.

Authors:  William A Hammond; Abhisek Swaika; Kabir Mody
Journal:  Ther Adv Med Oncol       Date:  2016-01       Impact factor: 8.168

Review 3.  Tumour heterogeneity: principles and practical consequences.

Authors:  Giorgio Stanta; Stephan Wenzel Jahn; Serena Bonin; Gerald Hoefler
Journal:  Virchows Arch       Date:  2016-07-13       Impact factor: 4.064

Review 4.  The biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized care.

Authors:  Marina De Rosa; Daniela Rega; Valeria Costabile; Francesca Duraturo; Antonello Niglio; Paola Izzo; Ugo Pace; Paolo Delrio
Journal:  Therap Adv Gastroenterol       Date:  2016-08-07       Impact factor: 4.409

5.  Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?

Authors:  Serena Bonin
Journal:  EBioMedicine       Date:  2015-06-12       Impact factor: 8.143

6.  A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.

Authors:  Shun-Ichi Suzuki; Satoshi Matsusaka; Mitsuharu Hirai; Harumi Shibata; Koichi Takagi; Nobuyuki Mizunuma; Kiyohiko Hatake
Journal:  Int J Oncol       Date:  2015-04-30       Impact factor: 5.650

7.  SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline.

Authors:  Maxime Guéguinou; Thomas Harnois; David Crottes; Arnaud Uguen; Nadine Deliot; Audrey Gambade; Aurélie Chantôme; Jean Pierre Haelters; Paul Alain Jaffrès; Marie Lise Jourdan; Günther Weber; Olivier Soriani; Philippe Bougnoux; Olivier Mignen; Nicolas Bourmeyster; Bruno Constantin; Thierry Lecomte; Christophe Vandier; Marie Potier-Cartereau
Journal:  Oncotarget       Date:  2016-06-14

Review 8.  DMET™ (Drug Metabolism Enzymes and Transporters): a pharmacogenomic platform for precision medicine.

Authors:  Mariamena Arbitrio; Maria Teresa Di Martino; Francesca Scionti; Giuseppe Agapito; Pietro Hiram Guzzi; Mario Cannataro; Pierfrancesco Tassone; Pierosandro Tagliaferri
Journal:  Oncotarget       Date:  2016-08-16

9.  BRAF, KRAS and PIK3CA Mutation and Sensitivity to Trastuzumab in Breast Cancer Cell Line Model

Authors:  Satyajit Patra; Vanesa Young; Leslie Llewellyn; Jitendra N Senapati; Jesil Mathew
Journal:  Asian Pac J Cancer Prev       Date:  2017-08-27

10.  Clinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.

Authors:  Andrew Dean; Aisling Byrne; Mira Marinova; Ingrid Hayden
Journal:  Biomed Res Int       Date:  2016-07-21       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.